Arrowhead Pharmaceuticals Inc
(FRA:HDP1)
€
24.79
0.13 (0.53%)
Market Cap: 3.07 Bil
Enterprise Value: 2.91 Bil
PE Ratio: 0
PB Ratio: 17.46
GF Score: 53/100 Arrowhead Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2022 / 08:35PM GMT
Release Date Price:
€31.29
(+4.23%)
Luca Issi
RBC Capital Markets - Analyst
Great. Thanks. Hello, everybody. Luca Issi, senior biotech analyst here at RBC Capital Markets. And today, it's our great privilege to have Arrowhead Pharma here with us for a fireside chat. Representing the company, we have Vince Anzalone, Head of IR. Vince, thanks again for joining us. How are you doing today?
Vince Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR
Great. Thank you, Luca, and thank you to the whole RBC team for having us today. Great day. Thank you.
Questions & Answers
Luca Issi
RBC Capital Markets - Analyst
Terrific. Terrific. We have a long list of questions here for individual programs, but, maybe before we talk about individual program, can you just maybe give us a high-level overview of Arrowhead, maybe what progress the organization has made in the last few months, and, most importantly, what's ahead?
Vince Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR
Sure. So I think the way I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot